HormoneFDA Approved

Lanreotide

A long-acting somatostatin analog marketed as Somatuline Depot and used in neuroendocrine and acromegaly-related care.

Somatostatin AnalogFDA ApprovedAcromegalyNeuroendocrine

Also referenced as: Somatuline Depot, Lanreotide Acetate

Public product evidenceSearch the public certificate ledger for this compoundNo exact compound records are currently indexed under this profile name.
Status
FDA Approved

This peptide maps to at least one regulated medical product or label context in the United States.

Research area
Hormone signaling research

This profile is grouped by its dominant research area, not by vendor shelf placement.

Aliases
2

Somatuline Depot, Lanreotide Acetate

Signal depth
High

FDA label signal · 124 trials · 1233 PubMed results

Established
Research evidence

Lanreotide is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.

Lanreotide has 58 name-matched clinical trials (1 international) (highest phase: Phase 4) and 1233 PubMed-indexed publications and holds an FDA drug label. 19 trials have posted results.

🌍 1 international trialFAERS (approved drug): 4,759
Human data
Approved drug
Trial quality
Large RCT
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
Top-tier journals
PHASE4 · RandomizedA Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus LanreotidePHASE4Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NETPHASE4 · RandomizedComparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient SatisfactionISRCTNAssessment of the efficacy of Lanreotide Autogel® in the reversal of sleep apnoea, left ventricular hypertrophy and hypertension when used as primary medical therapy in acromegalyNew England Journal of Medicine · 1,945 citationsLanreotide in Metastatic Enteropancreatic Neuroendocrine TumorsJournal of Clinical Oncology · 500 citationsProspective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors—The International Lanreotide and Interferon Alfa Study Group
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What lanreotide is

Lanreotide is a long-acting somatostatin analog best known in the United States as Somatuline Depot.

Why it matters

It rounds out the approved somatostatin-analog side of the peptide library and gives users a more complete picture of serious peptide therapeutics in endocrine medicine.

Regulatory context

Lanreotide is FDA approved in the United States.

Practical reading note

When a peptide has deep real-world use in medicine, it often deserves a page even if it is not a gray-market conversation magnet.